Comparable stake leader
PROEHL GERALD T
SEC ownership of Dermata Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001853816.
Disclosed value leader
Proehl Investment Ventures LLC
Comparable rows
18/29
Latest evidence
30 Jun 2026
- Public ticker
- DRMA, DRMAW on Nasdaq
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
PROEHL GERALD T
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
18 of 29
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
PROEHL GERALD T
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001853816
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Dermata Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
PROEHL GERALD T
Disclosed value leader
Proehl Investment Venture...
Comparable rows
18/29
Latest evidence
30 Jun 2026
3/4/5
13D/G
13F
Lead comparable stake: 17%
11 rows are not safely comparable across share classes.
13D/G row: PROEHL GERALD T
Showing 1-8 of 29 holder rows.
Quick read
PROEHL GERALD T leads the comparable SEC ownership view at 17%.
18 of 29 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens PROEHL GERALD T's linked filing trail.
Comparable ownership
Top 5
PROEHL GERALD T
17%
Kyri K. van Hoose
9%
ARMISTICE CAPITAL, LLC
5%
INTRACOASTAL CAPITAL, LLC
5%
BIGGER CAPITAL FUND L P
1.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 29 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| PROEHL GERALD T |
3/4/5
13D/G
President, CEO and Chairman, Director, 10%+ Owner
|
17%
from 13D/G
|
$2,104,845
7,414,215 shares
mixed-class rows
|
— | 02 Jan 2026 |
| Kyri K. van Hoose |
13D/G
3/4/5
SVP, CFO
|
9%
|
$457,379
384,352 shares
|
$0 | 27 May 2026 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$151,487
53,910 shares
|
$0 | 31 Dec 2025 |
| INTRACOASTAL CAPITAL, LLC |
13D/G
Mitchell P. Kopin
|
5%
|
$147,872
211,246 shares
|
+$44,931 | 31 Mar 2026 |
| BIGGER CAPITAL FUND L P |
13D/G
|
1.9%
|
—
75,200 shares
|
$0 | 31 Mar 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.47%
|
$26,061
20,203 shares
|
— | 30 Jun 2026 |
| WELCH & FORBES LLC |
13F
Company
|
0.47%
|
$25,800
20,000 shares
|
— | 30 Jun 2026 |
| STATE STREET CORP |
13F
Company
|
0.44%
|
$24,184
18,747 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$1,257.
Buys
$1,270
Insiders: 1
Sells
$13.09
Insiders: 1
Net
+$1,257
Shares: +989
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 1,000
Shares: 11
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 11 | $0 | $13.09 | -$13.09 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 1,000 | 0 | $1,270 | $0 | +$1,270 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-13 of 13 reporting-owner rows connected to Dermata Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
13
Largest Forms 3/4/5 holder
Proehl Investment Ventures LLC
Net 12M change
+$1,257
Latest report
16 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Proehl Investment Ventures LLC | 10%+ Owner | $6,973,306 | Mixed | 17 Aug 2021 | ||
| PROEHL GERALD T | President, CEO and Chairman, Director, 10%+ Owner | $2,104,845 | Mixed | 02 Jan 2026 | ||
| Kyri K. van Hoose | Svp, Cfo | $299,877 | Median | 16 Aug 2026 | ||
| Thomas Insley | Chief Financial Officer | $34,409 | Mixed | 17 Aug 2021 | ||
| Maria E. Bedoya Toro | SVP, Regulatory Affairs | $1,327 | +$1,270 | +2228% | Mixed | 17 Feb 2026 |
| Kathleen D. Scott | Director | $1 | -$13 | -93% | Mixed | 16 Jun 2026 |
| Christopher J. Nardo | Senior VP, CDO | Mixed | 02 Jan 2026 | |||
| Brittany Bradrick | Director | Mixed | 02 Jan 2026 | |||
| HALE DAVID F | Director | Mixed | 02 Jan 2026 | |||
| Wendell Wierenga | Director | Mixed | 02 Jan 2026 | |||
| Mary Fisher | Director | Mixed | 02 Jan 2026 | |||
| Steven J. Mento | Director | Mixed | 02 Jan 2026 | |||
| Andrew Seth Sandler | Director | Mixed | 02 Jan 2026 |
Recent insider transactions for Dermata Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Proehl Gerald T | DRMA | Common Stock | Award | 138.8% | 170,068 | 292,631 | 16 Aug 2026 | By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020 | ||
| Proehl Gerald T | DRMA | Pre-Funded Warrant (Right to Buy) | Award | 1,360,544 | 1,360,544 | 16 Aug 2026 | By Proehl Investment Ventures LLC | |||
| Proehl Gerald T | DRMA | Series F Warrant (Right to Buy) | Award | 170,068 | 170,068 | 16 Aug 2026 | By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020 | |||
| Proehl Gerald T | DRMA | Series E Warrant (Right to Buy) | Award | 170,068 | 170,068 | 16 Aug 2026 | By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020 | |||
| Proehl Gerald T | DRMA | Series F Warrant (Right to Buy) | Award | 1,360,544 | 1,360,544 | 16 Aug 2026 | By Proehl Investment Ventures LLC | |||
| Proehl Gerald T | DRMA | Series E Warrant (Right to Buy) | Award | 1,360,544 | 1,360,544 | 16 Aug 2026 | By Proehl Investment Ventures LLC | |||
| Kyri K. van Hoose | DRMA | Common Stock | Award | 78.2% | 102,040 | 232,463 | 16 Aug 2026 | Direct | ||
| Kyri K. van Hoose | DRMA | Series F Warrant (Right to Buy) | Award | 102,040 | 102,040 | 16 Aug 2026 | Direct | |||
| Kyri K. van Hoose | DRMA | Series E Warrant (Right to Buy) | Award | 102,040 | 102,040 | 16 Aug 2026 | Direct | |||
| Kathleen D. Scott | DRMA | Common Stock | Sale | -100% | $13.09 | $1.19 | -11 | 0 | 16 Jun 2026 | Direct |
| Maria E. Bedoya Toro | DRMA | Common Stock | Purchase | 8333.3% | $1,270 | $1.27 | 1,000 | 1,012 | 17 Feb 2026 | Direct |
| Proehl Gerald T | DRMA | Stock Option (right to buy) | Award | 37,500 | 37,500 | 02 Jan 2026 | Direct | |||
| Hale David F | DRMA | Stock Option (Right to Buy) | Award | 2,500 | 2,500 | 02 Jan 2026 | Direct | |||
| Wendell Wierenga | DRMA | Stock Option (Right to Buy) | Award | 2,500 | 2,500 | 02 Jan 2026 | Direct | |||
| Maria E. Bedoya Toro | DRMA | Stock Option (right to buy) | Award | 9,000 | 9,000 | 02 Jan 2026 | Direct | |||
| Kathleen D. Scott | DRMA | Stock Option (Right to Buy) | Award | 2,500 | 2,500 | 02 Jan 2026 | Direct | |||
| Andrew Seth Sandler | DRMA | Stock Option (Right to Buy) | Award | 2,500 | 2,500 | 02 Jan 2026 | Direct | |||
| Christopher J. Nardo | DRMA | Stock Option (right to buy) | Award | 18,000 | 18,000 | 02 Jan 2026 | Direct | |||
| Kyri K. van Hoose | DRMA | Stock Option (right to buy) | Award | 18,000 | 18,000 | 02 Jan 2026 | Direct | |||
| Steven J. Mento | DRMA | Stock Option (Right to Buy) | Award | 2,500 | 2,500 | 02 Jan 2026 | Direct | |||
| Mary Fisher | DRMA | Stock Option (Right to Buy) | Award | 2,500 | 2,500 | 02 Jan 2026 | Direct | |||
| Brittany Bradrick | DRMA | Stock Option (Right to Buy) | Award | 2,500 | 2,500 | 02 Jan 2026 | Direct | |||
| Kyri K. van Hoose | DRMA | Common Stock | Award | 1556.4% | 122,549 | 130,423 | 23 Dec 2025 | Direct | ||
| Kyri K. van Hoose | DRMA | Warrant (Right to Buy) | Award | 7,874 | 7,874 | 23 Dec 2025 | Direct | |||
| Kyri K. van Hoose | DRMA | Warrant (Right to Buy) | Disposed to Issuer | 7,874 | 0 | 23 Dec 2025 | Direct | |||
| Kyri K. van Hoose | DRMA | Series D Warrant (Right to Buy) | Award | 122,549 | 122,549 | 23 Dec 2025 | Direct | |||
| Kyri K. van Hoose | DRMA | Series C Warrant (Right to Buy) | Award | 122,549 | 122,549 | 23 Dec 2025 | Direct | |||
| Proehl Gerald T | DRMA | Common Stock | Award | 875350% | 122,549 | 122,563 | 23 Dec 2025 | By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020 | ||
| Proehl Gerald T | DRMA | Common Stock | Award | 830840.7% | 490,196 | 490,255 | 23 Dec 2025 | By Proehl Family Trust | ||
| Proehl Gerald T | DRMA | Warrant (Right to Buy) | Award | 78,740 | 78,740 | 23 Dec 2025 | Direct | |||
| Proehl Gerald T | DRMA | Warrant (Right to Buy) | Disposed to Issuer | 78,740 | 0 | 23 Dec 2025 | Direct | |||
| Proehl Gerald T | DRMA | Series D Warrant (Right to Buy) | Award | 122,549 | 122,549 | 23 Dec 2025 | By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020 | |||
| Proehl Gerald T | DRMA | Series C Warrant (Right to Buy) | Award | 122,549 | 122,549 | 23 Dec 2025 | By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020 | |||
| Proehl Gerald T | DRMA | Series D Warrant (Right to Buy) | Award | 163398.7% | 490,196 | 490,496 | 23 Dec 2025 | By Proehl Family Trust | ||
| Proehl Gerald T | DRMA | Series C Warrant (Right to Buy) | Award | 163398.7% | 490,196 | 490,496 | 23 Dec 2025 | By Proehl Family Trust |
* marks a reported price that did not pass the local price check.